Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features

被引:18
作者
Rommasi, Foad [1 ]
Nasiri, Mohammad Javad [2 ]
Mirsaeidi, Mehdi [3 ]
机构
[1] Shahid Beheshti Univ, Fac Life Sci & Biotechnol, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran
[3] Univ Miami, Miller Sch Med, Dept Pulm & Crit Care, Miami, FL 33136 USA
关键词
SARS-CoV-2; Pathophysiology; COVID-19; treatment; Inflammatory responses; Immunosuppressive agents; Cytokine storm; NECROSIS-FACTOR-ALPHA; CORONAVIRUS DISEASE 2019; RHEUMATOID-ARTHRITIS; CLINICAL PHARMACOKINETICS; RECEPTOR ANTAGONIST; IN-VITRO; ABSOLUTE BIOAVAILABILITY; COLCHICINE THERAPY; CYTOKINE STORM; MELATONIN;
D O I
10.1007/s11010-021-04325-9
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuhan, China, physicians, researchers, and others have made it their top priority to find drugs and cures that can effectively treat patients and reduce mortality rates. The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. Degenerative virus analyses of the infection incidence and COVID-19 have demonstrated that SARS-CoV-2 penetrates the pulmonary alveoli's endothelial cells through Angiotensin-Converting Enzyme 2 (ACE2) receptors on the membrane, stimulates various signaling pathways and causes excessive secretion of cytokines. The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, cause a severe condition in the COVID-19 patients, which is called "cytokine storm". It can lead to acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator support. Various drugs, including immunomodulatory and immunosuppressive agents (e.g., monoclonal antibodies (mAbs) and interleukin antagonists) have been utilized in clinical trials. However, the studies and clinical trials have documented diverging findings, which seem to be due to the differences in these drugs' possible mechanisms of action. These drugs' mechanism of action generally includes suppressing or modulating the immune system, preventing the development of cytokine storm via various signaling pathways, and enhancing the blood vessels' diameter in the lungs. In this review article, multiple medications from different drug families are discussed, and their possible mechanisms of action are also described.
引用
收藏
页码:711 / 726
页数:16
相关论文
共 161 条
  • [21] Statin therapy in COVID-19 infection
    Castiglione, Vincenzo
    Chiriaco, Martina
    Emdin, Michele
    Taddei, Stefano
    Vergaro, Giuseppe
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (04) : 258 - 259
  • [22] Regulatory T Cells in Arterivirus and Coronavirus Infections: Do They Protect Against Disease or Enhance it?
    Cecere, Thomas E.
    Todd, S. Michelle
    LeRoith, Tanya
    [J]. VIRUSES-BASEL, 2012, 4 (05): : 833 - 846
  • [23] Chang Shao-hong, 2004, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V20, P484
  • [24] Chansrichavala P, 2009, ASIAN PAC J ALLERGY, V27, P49
  • [25] COLCHICINE - RECENT PHARMACOKINETIC AND CLINICAL PHARMACOLOGICAL DATA
    CHAPPEY, O
    SCHERRMANN, JM
    [J]. REVUE DE MEDECINE INTERNE, 1995, 16 (10): : 782 - 789
  • [26] Charles P, 1999, J IMMUNOL, V163, P1521
  • [27] Clinical and immunological features of severe and moderate coronavirus disease 2019
    Chen, Guang
    Wu, Di
    Guo, Wei
    Cao, Yong
    Huang, Da
    Wang, Hongwu
    Wang, Tao
    Zhang, Xiaoyun
    Chen, Huilong
    Yu, Haijing
    Zhang, Xiaoping
    Zhang, Minxia
    Wu, Shiji
    Song, Jianxin
    Chen, Tao
    Han, Meifang
    Li, Shusheng
    Luo, Xiaoping
    Zhao, Jianping
    Ning, Qin
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (05) : 2620 - 2629
  • [28] Management of cytokine release syndrome related to CAR-T cell therapy
    Chen, Hongli
    Wang, Fangxia
    Zhang, Pengyu
    Zhang, Yilin
    Chen, Yinxia
    Fan, Xiaohu
    Cao, Xingmei
    Liu, Jie
    Yang, Yun
    Wang, Baiyan
    Lei, Bo
    Gu, Liufang
    Bai, Ju
    Wei, Lili
    Zhang, Ruili
    Zhuang, Qiuchuan
    Zhang, Wanggang
    Zhao, Wanhong
    He, Aili
    [J]. FRONTIERS OF MEDICINE, 2019, 13 (05) : 610 - 617
  • [29] Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis
    Cheung, Ka Shing
    Hung, Ivan F. N.
    Chan, Pierre P. Y.
    Lung, K. C.
    Tso, Eugene
    Liu, Raymond
    Ng, Y. Y.
    Chu, Man Y.
    Chung, Tom W. H.
    Tam, Anthony Raymond
    Yip, Cyril C. Y.
    Leung, Kit-Hang
    Fung, Agnes Yim-Fong
    Zhang, Ricky R.
    Lin, Yansheng
    Cheng, Ho Ming
    Zhang, Anna J. X.
    To, Kelvin K. W.
    Chan, Kwok-H
    Yuen, Kwok-Y
    Leung, Wai K.
    [J]. GASTROENTEROLOGY, 2020, 159 (01) : 81 - 95
  • [30] CLINICAL-PHARMACOLOGY OF FAMOTIDINE - A SUMMARY
    CHREMOS, AN
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 1987, 9 : 7 - 12